Virus News and Research

Latest Virus News and Research

Study explains importance of identifying global pandemic risk factors to predict spread of diseases

A recent study led by Dr. Parviez Hosseini, a senior research fellow from EcoHealth Alliance (formerly Wildlife Trust), explains the importance of identifying global pandemic risk factors as early as possible, in order to predict the spread of diseases like H1N1 "swine" flu and SARS. "Predictive Power of Air Travel and Socio-Economic data for Early Pandemic Spread," recently published in the scientific publication PLoS ONE, examines the interplay among travel, trade, and national healthcare resources in predicting the emergence and spread of H1N1 and other viruses.

7 Oct 2010

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI).

7 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

New reference material to standardize gene therapy protocols in clinical trials

The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum

7 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

7 Oct 2010

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

A ground-breaking system for predicting how individual patients with HIV and AIDS will respond to different drugs is launched today by RDI, a UK-based not-for-profit research group. The experimental system, called the HIV Treatment Response Prediction System (HIV-TRePS), is available free of charge over the Internet and helps physicians select the best treatment for their patients.

6 Oct 2010

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced the award of a Fast Track SBIR from the Division of AIDS, National Institutes of Health for $3.1M to support the development of the Company's Transition State Vaccine (TSV) technology for a prophylactic HIV Vaccine.

6 Oct 2010

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.

6 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

Gen-Probe submits 510(k) application to FDA for APTIMA Trichomonas vaginalis assay on TIGRIS system

Gen-Probe Incorporated announced today that the Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

5 Oct 2010

Maternal influenza vaccination prevents flu in infants

Babies whose mothers who receive influenza vaccines while pregnant appear less likely to be infected with flu or hospitalized for respiratory illnesses in their first six months of life, according to a report posted online today that will appear in the February 2011 print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

5 Oct 2010

CPS recommends all Canadian babies should be vaccinated against rotavirus

All Canadian babies should be vaccinated against rotavirus, according to a new statement by the Canadian Paediatric Society. The CPS is also calling for public funding of the vaccine, which is not currently covered by provincial or territorial health plans.

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons.

4 Oct 2010

Researchers examine new genes to control mosquito-borne diseases

An Iowa State University researcher searched for new genes that are turned on during infection in a type of mosquito that is not only a pest, but transmits disease-causing pathogens.

4 Oct 2010

Research on immune system paves way to combat mother-to-infant HIV transmission

Researchers at Oregon Health &Science University may have uncovered a new weapon for combating HIV as it is passed from mother to newborn child. The research, which was led by researchers at OHSU's Oregon National Primate Research Center, will be published in the October 3rd online edition of the journal Nature Medicine.

4 Oct 2010

NIH awards Scripps Research grants to study the mechanisms of protein complex

For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.

4 Oct 2010

Suspected hand, foot and mouth disease on Denver flight

Two children arrived on a flight from Mexico to Denver showing symptoms of the contagious illness called ‘hand, foot and mouth’ disease (HFMD) and were checked by paramedics. They were allowed to leave after experts said they were no threat to public health.

4 Oct 2010

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

New data on multiple Bristol-Myers Squibb Company compounds will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 29 to November 2.

3 Oct 2010

Virus News and Research

Latest Virus News and Research

Study explains importance of identifying global pandemic risk factors to predict spread of diseases

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

Roche receives development and commercialization rights for danoprevir drug

New reference material to standardize gene therapy protocols in clinical trials

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

cobas TaqScreen DPX Test now available with CE Mark: Roche

Gen-Probe submits 510(k) application to FDA for APTIMA Trichomonas vaginalis assay on TIGRIS system

Maternal influenza vaccination prevents flu in infants

CPS recommends all Canadian babies should be vaccinated against rotavirus

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Researchers examine new genes to control mosquito-borne diseases

Research on immune system paves way to combat mother-to-infant HIV transmission

NIH awards Scripps Research grants to study the mechanisms of protein complex

Suspected hand, foot and mouth disease on Denver flight

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in